Every 10-Q that SYRA HEALTH CORP A (SYRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRA filings page.
Syra Health Corp. reported improved results for the three and six months ended June 30, 2026. Net revenues were $4,667,943 for the six months, up from $3,803,973, driven by growth in population health and healthcare workforce services. For the same period, net income was $491,221 versus a net loss of $535,861 in 2025, reflecting higher gross profit and lower operating expenses. Cash and cash equivalents were $2,123,747 and working capital was $2,551,002 as of June 30, 2026, with net cash provided by operating activities of $643,183.
Despite these gains, management states that there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months without additional capital, citing early-stage operations and limited visibility on revenues. The company also highlights significant customer concentration and dependence on government-related contracts. Subsequent to quarter-end, Syra obtained contract extensions with several customers and disclosed an anticipated CMS ACCESS Model partnership that it expects to be a durable revenue source over ten years.
Syra Health Corp. reported a profitable quarter for the three months ended March 31, 2026, with net revenues of $2,273,520, up about 22% from 2025, and net income of $240,979 versus a prior-year loss. Growth was driven by a $557,961 increase in population health revenue, partly offset by lower healthcare workforce revenue.
Gross profit rose to $971,255, lifting gross margin to roughly 43% as operating expenses fell by $282,218. Cash and cash equivalents increased to $2,922,318 and working capital to $2,345,509. However, management states there is still substantial doubt about the company’s ability to continue as a going concern, noting an accumulated deficit of $9,479,547 and the need to raise additional capital. The business remains highly dependent on government-related contracts and faces funding pressure from changes in U.S. federal spending.
Syra Health (SYRA) filed its Q3 2025 10‑Q, showing a smaller loss alongside a shift in revenue mix and a going concern warning. For the nine months ended September 30, 2025, net revenues were $5,491,944 versus $5,975,357 a year ago, as Healthcare Workforce declined and Population Health grew. Gross profit was $1,896,592 with a gross margin near 35%, up from roughly 22% last year, driven by mix toward higher‑margin project work.
Operating loss was $768,663 and net loss was $761,763, improving from $3,254,841 last year. Cash and cash equivalents were $1,976,545 as of September 30, 2025, with working capital of $2,156,762. The company disclosed substantial doubt about its ability to continue as a going concern and may need additional capital. Customer concentration remained high; Indiana FSSA accounted for approximately 37% of year‑to‑date revenue.
Corporate updates noted an April 11, 2025 voluntary delisting from Nasdaq to OTC QB and leadership changes in June, including appointment of an interim CEO. Class A shares outstanding were 11,339,169 as of November 11, 2025.